Our Globally Acclaimed Research Innovations

Among our most transformative breakthroughs are VRP-034, a first-in-class supramolecular cationic formulation of polymyxin B sulphate. Developed using VMRC’s proprietary Renal Guard Technology, VRP-034 addresses one of the most critical limitations of polymyxin therapy, dose-limiting nephrotoxicity. While polymyxin B is a last-resort antibiotic used for life-threatening MDR Gram-negative infections, its conventional form causes acute kidney injury in up to 60% of patients.

VRP-034 demonstrated up to 70% reduction in nephrotoxicity without compromising antimicrobial efficacy, validated across advanced human kidney-on-a-chip systems and transplant kidney models. This innovation has not only received Qualified Infectious Disease Product (QIDP) status from the US FDA but has also been featured in prestigious peer-reviewed journals, including Antimicrobial Agents and Chemotherapy, IJAA, JAC-AMR, and Antibiotics. Additionally, the scientific data have been presented at leading global conferences such as ASM/ESCMID, ECCMID, BSAC, and ASM Microbe, underscoring broad international recognition.

To protect our innovation globally, we have filed patents for VRP-034 in over 88 countries, with grants already secured in more than 10 nations, including India and several strategic international markets.

Our innovation is not just limited to this. With the development of CRISPR-Cas-based gene editing platforms, we advanced next-generation therapeutics with a sharper clinical focus. Global recognition followed: three of our pipeline drug candidates were featured in the WHO’s 2023 Global Antibacterial Pipeline Report, reaffirming our global relevance in the AMR space

This same spirit of purpose led to a defining strategic moment- the in-licensing of MET-X from INFEX Therapeutics, UK. MET-X, a novel β-lactamase inhibitor targeting MBL-producing pathogens, strengthens our AMR pipeline with strategic depth and the potential for global clinical impact. This is more than a partnership- it is a breakthrough commitment to addressing drug resistance at scale and reaffirming our responsibility to India’s healthcare ecosystem.

What We Do

We owe our existence and growth to Research and Development. With strong commitment, VMRC has metamorphosed itself into the leaders providing  innovative solutions to the unmet medical needs in the field of  Anti-Microbial Resistance (AMR), Oncology, Wound care, Pain management.  Our GLP accredited labs are committed to bringing to the world novel  breakthroughs that cater to critical care and super specialty segment.  We have the right blend of the spectrum, vision, talent and capabilities that we enabling us to actualize our goals.